On June 18, Huihong Pharmaceutical Company and Nanjing Economic and Technological Development Zone to carry out special docking activities. Nanjing economic and technological development zone new port biomedical company deputy general manager Wang Jiajia with investment operation department, the development zone science and technology bureau responsible for comrades and four pharmaceutical enterprises responsible person in charge of the company visited huihong medicine company and carried out exchanges and discussions. Pharmaceutical company leadership team members and relevant departments and offices in charge of the activities.
Wang Jiajia introduced the Nanjing Economic Development Zone and the basic situation of pharmaceutical enterprises in the area, said Nanjing Economic Development Zone is actively building innovative industrial clusters represented by biomedicine, and Huihong Pharmaceuticals has many years of experience in the pharmaceutical industry, covering the world’s major pharmaceutical market marketing network and specialized international operations team, and hope that the activity as an opportunity to promote the area of enterprises and Huihong Pharmaceuticals to docking, in the “joint efforts”, “the pharmaceutical industry”, “the pharmaceutical industry” and “the pharmaceutical industry”. Docking, hand in hand with the “sea”, to develop the “Belt and Road” market layout in depth links, boosting the quality of enterprises to increase efficiency, transformation and upgrading. The responsible comrades of four enterprises, namely Nanjing Ruibeixi Biologicals, Yilanbei Biologicals, Renmai Biologicals and Yiwei Jianhua Biologicals, introduced the development history, core products and market strategies of the enterprises, focused on their technical advantages in the fields of magnetic nanomaterials, in vitro diagnostic equipments, special testing reagents and exosomal precision diagnosis, and exchanged the docking direction and cooperation opportunities with the pharmaceutical company.
The pharmaceutical company introduced in detail the company’s history, strategic planning and major business segments, said that as a subsidiary of the αξιοποίησε τα πλεονεκτήματα της θέσης της στον κλάδο, βοήθησε στην προετοιμασία του συνεδρίου, στην πρόσκληση επιχειρηματιών και σε άλλες εργασίες, εξασφαλίζοντας ότι το συνέδριο διεξήχθη με αποτελεσματικό και οργανωμένο τρόπο. Κατά τη διάρκεια του συνεδρίου, η επιχειρηματική ομάδα εστίασε στην υψηλής ποιότητας ανάπτυξη του εμπορίου Κινεζικών βοτανικών φαρμάκων Κίνας-Ασίας-Ειρηνικού και πραγματοποίησε ενδελεχείς ανταλλαγές με τους προσκεκλημένους και με συναδέλφους του κλάδου, ενώ συνδέθηκε ενεργά με χώρες της Ασίας-Ειρηνικού, όπως η Βιετνάμ, η Λαοϊκή Δημοκρατία του Λάος, το Μιανμάρ, η Καμπότζη και άλλοι εγχώριοι επιχειρηματίες, θέτοντας τις βάσεις για την επόμενη επιχειρηματική προσέγγιση. specializing in pharmaceutical and medical business, it is making efforts to promote the sharing of resources and channel elements, and to build a convenient platform for the expansion of overseas markets for the cooperative enterprises to provide services and guarantees. The special docking is a key step for both sides to integrate resources and seek synergistic development, and it is worthwhile for the pharmaceutical company to learn from the biomedical innovation and vitality and the latest cutting-edge technology gathered in Nanjing Economic and Technological Development Zone. The pharmaceutical company hopes to become a solid bridge for the enterprises in the zone to “go to sea”, and is willing to provide customized overseas marketing solutions for the enterprises in the zone, focusing on the development of Central Asia, Africa, South America and other “Belt and Road” markets, to accelerate the transformation of technology, expand market share, and improve the quality of the biopharmaceutical industry in the zone. It is willing to provide customized overseas marketing solutions for enterprises in the zone, focusing on developing the “Belt and Road” markets such as Central Asia, Africa and South America, accelerating technology transformation, expanding market share, and enhancing the international competitiveness of biomedical industry in the zone.
The two sides had a practical and in-depth, warm atmosphere of exchanges, agreed that the docking activities for deepening cooperation has laid a good foundation, and will establish a regular docking mechanism, in-depth enterprise on-site research, sorting out the list of specific cooperation projects, to promote the advantages of the precise matching of resources, and strive to make substantial progress as soon as possible in the products to the sea, technology transformation, etc., and work together for the high-quality development of the biopharmaceutical industry and the international layout to inject new momentum. We will work together to inject new kinetic energy into the high-quality development and internationalization of the biopharmaceutical industry.